Become a strategic partner for the industrialisation and commercialisation
of this innovation through an operating licence.
MICKEY
Prediction and treatment of rejection risk in kidney transplantation
Investment: 100k€
Scope: Healthcare
Scientific field(s): Biology and Medicinal Chemistry
Institution(s): Université Paris-Saclay- INSERM- Gustave Roussy
Development: Technology to be marketed
#1
A non-invasive predictive biomarker for personalized immunosuppression
#2
Reduced risk of rejection and long-term nephrotoxicity
#3
Complementary, clinically realistic, and rapidly transferable approach
USE CASES
Kidney transplantation is the best treatment for end-stage renal disease. However, transplant outcomes are linked to the use of immunosuppressive medications to prevent graft rejection and the new kidney function recovery. However, these outcomes are sometimes hampered, more especially due to the long-term nephrotoxicity of these immunosuppressive treatments. Thus, it appears crucial to be able to adapt the immunosuppressive treatment and to improve immune tolerance in transplant recipients.
APPLICATIONS
The project aims to develop a predictive biomarker of the efficiency of the immunosuppressive treatment in kidney transplant recipients allowing to tailor treatment and reduce the risk of kidney transplant rejection. Moreover, a preconditioning treatment to improve immune tolerance in transplant recipients receiving immunosuppressive treatment will also be investigated.
ADVANTAGES
- Non-invasive approach to identify responder patient
- Complementary treatment with human produced molecule already used in clinical application